NANOCOPD

Bioorthogonal nanoparticles for COPD theranostics. NANOCOPD

InstitutionPrincipal InvestigatorOther researches
CIBERES (coordinator group) Fernando Herranz
  • José Ruiz-Cabello
  • Beatriz Salinas
  • Hugo Groult
  • Juan Pellico
SEPAR Germán Peces-Barba
  • N. González Mangado
  • Sandra Pérez Rial
  • Álvaro Girón Martínez
  • Raúl Terrón Expósito
CIBER-BBN Neus Ferrer Miralles
  • Antonio Villaverde
  • Esther Vázquez Gómez
  • José Luis Corchero
  • Elena García Fruitos
  • Rosa Mendoza Moreno
  • Paolo Saccardo
  • Xu Zhikun

Chronic Obstructive Pulmonary Disease (COPD) is defined, in clinical practice, by its characteristically low airflow on lung function tests. It was the sixth leading cause of death in 1990 and it is projected to be the fourth leading cause of death worldwide by 2030 due to an increase in smoking rates and demographic changes in many countries. There is no early diagnosis test to improve the prognosis of the patients, furthermore there is no fully effective treatment for the disease.

The goal of the project is the creation of different nanoprobes for the multimodal molecular imaging of COPD, using magnetic resonance imaging and fluorescence tomography. The nanoagents will show long circulating times in blood and accumulation in the lung. The project will be developed in a two-way approach addressing both, COPD lesion and reparation. The nanoprobes will be developed using a combination of bioorthogonal chemical techniques and recombinant technology for the modification of the different biomolecules.

The main clinical need this project will address is one of the most important, an early and effective diagnosis through the use of molecular imaging, allowing optimizing disease prevention, improving symptom control or preventing disease progression.